Though there were no proven cases of ZIKV transmission through blood transfusion in the U.S., the FDA designated the virus as a “relevant transfusion-transmitted infection” (RTTI) in 2016. As a result, all blood donors from 2016-21 were tested for Zika virus using an FDA-approved nucleic acid test, most commonly one that tested multiple donors at the same time (mini-pool NAT), unless the product was pathogen-reduced.
In 2021, after analyzing data showing no positive blood donations since 2018, the FDA removed the “RTTI” designation from ZIKV (see their rationale here). Most US blood centers stopped testing blood donors for ZIKV by mid-2021.
Back to Glossary List